159 related articles for article (PubMed ID: 16895673)
1. [Anticancer drug-induced nephrotoxicity].
Isnard-Bagnis C; Moulin B; Launay-Vacher V; Izzedine H; Tostivint I; Deray G
Nephrol Ther; 2005 May; 1(2):101-14. PubMed ID: 16895673
[TBL] [Abstract][Full Text] [Related]
2. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of cisplatin-induced nephrotoxicity in rats by tetramethylpyrazine, a major constituent of the Chinese herb Ligusticum wallichi.
Ali BH; Al-Moundhri M; Eldin MT; Nemmar A; Al-Siyabi S; Annamalai K
Exp Biol Med (Maywood); 2008 Jul; 233(7):891-6. PubMed ID: 18445776
[TBL] [Abstract][Full Text] [Related]
4. [Prevention and management of nephrotoxicity from anti-cancer agents].
Miyazaki J; Kawai K
Nihon Rinsho; 2003 Jun; 61(6):973-7. PubMed ID: 12806945
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study.
Launay-Vacher V; Oudard S; Janus N; Gligorov J; Pourrat X; Rixe O; Morere JF; Beuzeboc P; Deray G;
Cancer; 2007 Sep; 110(6):1376-84. PubMed ID: 17634949
[TBL] [Abstract][Full Text] [Related]
6. Effects of different doses of hyperbaric oxygen on cisplatin-induced nephrotoxicity.
Aydinoz S; Uzun G; Cermik H; Atasoyu EM; Yildiz S; Karagoz B; Evrenkaya R
Ren Fail; 2007; 29(3):257-63. PubMed ID: 17497437
[TBL] [Abstract][Full Text] [Related]
7. Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
Lee CK; Park KK; Hwang JK; Lee SK; Chung WY
Phytother Res; 2009 Jul; 23(7):999-1005. PubMed ID: 19140122
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2.
Tanihara Y; Masuda S; Katsura T; Inui K
Biochem Pharmacol; 2009 Nov; 78(9):1263-71. PubMed ID: 19540211
[TBL] [Abstract][Full Text] [Related]
9. [Glutamin concentrations in patients treated with cisplatin have a predicting value of renal failure development].
Cobo M; Martín Gómez MA; Frutos MA; Benavides M
Nefrologia; 2007; 27(1):23-9. PubMed ID: 17402876
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man.
Powis G
Drug Metab Rev; 1983; 14(6):1145-63. PubMed ID: 6373208
[TBL] [Abstract][Full Text] [Related]
11. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.
Sánchez-González PD; López-Hernández FJ; López-Novoa JM; Morales AI
Crit Rev Toxicol; 2011 Nov; 41(10):803-21. PubMed ID: 21838551
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of renoprotective effect of Aphanizomenon flos-aquae on cisplatin-induced renal dysfunction in rats.
Kuriakose GC; Kurup MG
Ren Fail; 2008; 30(7):717-25. PubMed ID: 18704821
[TBL] [Abstract][Full Text] [Related]
13. Licochalcone A inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice.
Lee CK; Son SH; Park KK; Park JH; Lim SS; Kim SH; Chung WY
Basic Clin Pharmacol Toxicol; 2008 Jul; 103(1):48-54. PubMed ID: 18484961
[TBL] [Abstract][Full Text] [Related]
14. Prevention of cisplatin-induced nephrotoxicity by glucosides of ascorbic acid and alpha-tocopherol.
Maliakel DM; Kagiya TV; Nair CK
Exp Toxicol Pathol; 2008 Sep; 60(6):521-7. PubMed ID: 18644706
[TBL] [Abstract][Full Text] [Related]
15. [Renal complications of anti-cancer chemotherapy].
Fillastre JP; Moulin B; Godin M; Josse S
Pathol Biol (Paris); 1986 Nov; 34(9):1013-28. PubMed ID: 3543812
[TBL] [Abstract][Full Text] [Related]
16. Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice.
Nakashima-Kamimura N; Mori T; Ohsawa I; Asoh S; Ohta S
Cancer Chemother Pharmacol; 2009 Sep; 64(4):753-61. PubMed ID: 19148645
[TBL] [Abstract][Full Text] [Related]
17. [Dosage of drugs in patients with kidney diseases].
Kokot F
Wiad Lek; 1996; 49(7-12):87-91. PubMed ID: 9245115
[TBL] [Abstract][Full Text] [Related]
18. Effects of the anticancer dehydrotarplatin on cytochrome P450 and antioxidant enzymes in male rat tissues.
Nannelli A; Messina A; Marini S; Trasciatti S; Longo V; Gervasi PG
Arch Toxicol; 2007 Jul; 81(7):479-87. PubMed ID: 17364183
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity--what do we know and what don't we know?
Skinner R
J Pediatr Hematol Oncol; 2011 Mar; 33(2):128-34. PubMed ID: 21285904
[TBL] [Abstract][Full Text] [Related]
20. Time course of the change and amelioration of nedaplatin-induced nephrotoxicity in rats.
Uehara T; Tsuchiya N; Masuda A; Torii M; Nakamura M; Yamate J; Maruyama T
J Appl Toxicol; 2008 Apr; 28(3):388-98. PubMed ID: 17685399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
